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Abstract
Introduction Autologous lipotransfer is seen as an ideal
filler for soft tissue reconstruction. The main limitation of
this procedure is the unpredictable resorption and volume
loss of the fat graft. In the recent decade, an increasing
amount of research has focused on the use of adipose tis-
sue-derived stromal cells (ASCs) to enrich the fat graft, a
procedure termed cell-assisted lipotransfer (CAL). The aim
of this review was to systematically review the current
preclinical and clinical evidence for the efficacy of CAL
compared with conventional lipotransfer.
Materials and Methods A systematic search was per-
formed on PubMed and other databases to identify all
preclinical and clinical studies where CAL with ASCs was
compared with conventional lipotransfer. A total of 20
preclinical studies and seven clinical studies were included
in the review.
Results The preclinical studies consisted of 15 studies
using immunodeficient animal models and five studies
using immunocompetent studies. Seventeen studies exam-
ined weight/volume retention of which 15 studies favored
CAL over conventional lipotransfer. One clinical study did
not find any efficacy of CAL and the remaining six studies
favored CAL.
Conclusions The present evidence suggests that there is a
big potential for CAL in reconstructive surgery; however,
the present studies are so far still of low quality with
inherent weaknesses. Several aspects regarding CAL still
remain unknown such as the optimal degree of cell
enrichment and also its safety. Further high-quality studies
are needed to establish if CAL can live up to its potential.
Level of Evidence V This journal requires that authors
assign a level of evidence to each article. For a full
description of these Evidence-Based Medicine ratings,
please refer to the Table of Contents or the online
Instructions to Authors www.springer.com/00266.
Keywords Regenerative medicine  Stromal vascular
fraction  Adipose-derived stromal cell  Cell-assisted
lipotransfer  Fat graft
Introduction
Autologous fat transplantation for soft tissue augmentation
to reconstruct congenital or acquired tissue defects is an
increasingly ideal method in the field of plastic surgery.
Autologous fat transplantation was first described over a
century ago and is now seen as an ideal filler because it is
host compatible, readily available, and can be harvested
easily and repeatedly as needed without complications
arising from allergic or foreign body reactions. Although
adipose transfer has been widely used in clinical cases,
high variability in long-term results is being reported,
mainly due to unpredictable degrees of resorption and
volume loss with graft survival rate ranging from 20 to
90 % in the present literature [1–5]. The low survival rate
and high reabsorption rate of the transplanted fat reduce the
efficacy of this technique. Many have tried to standardize
different steps involved with lipotransfer but the survival
rate is still very variable.
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Because of the unpredictability associated with lipo-
transfer, researchers have sought to increase the survival
rate of the transplanted fat by addition of growth factors
such as insulin, vascular endothelial growth factor (VEGF),
and many others [6–10] but also by enriching the fat with
adipose tissue-derived stromal cells (ASCs) [11].
Thenumber ofASCs in adipose tissue is sopronounced that
they can be harvested, isolated, and used for treatment as an
autologous therapy in a single-stage procedure, which cir-
cumventsmany ethical and immunologic questions associated
with allogeneic/xenogeneic therapy. The stromal vascular
fraction (SVF) is obtained from lipoaspirate, and consists of a
heterogeneous group of cells including hematopoietic cells,
endothelial cells, pericytes, and stromal cells [12, 13]. When
these cells are cultured only the plastic adherent cells remain.
This cell population is termed ASCs and they are more
homologous in their phenotype than SVF cells and resemble
mesenchymal stem cells obtained from the bonemarrow [14].
In vivo models examining the use of SVF or ASCs for
enrichment of fat grafts were first introduced in 2006 by
Moseley et al. [15] and Matsumoto et al. [11] based on pre-
vious work by Llull and other unpublished work. Matsumoto
et al. [11] first introduced the term cell-assisted lipotransfer
(CAL) and since thenmanyothers have examined the efficacy
of this technique with slight variations and promising results
[16–20]. In recent years, the first human studies examining the
efficacy of CAL have also been published [21–23].
The aim of this article was to systematically identify and
review the current preclinical and clinical studies regarding
CAL to see what lessons can be learned so far and what the
current status of this technique is for clinical use.
Adipose-Derived Stromal Cells
The adipose tissue plays important physiological roles in
the human body as an endocrine organ and a site of energy
storage. It is also utilized surgically as a filler in soft tissue
augmentation for the correction of tissue defects or cos-
metic purposes. Additionally, adipose tissue is now rec-
ognized as a rich source of stromal stem cells, which has
opened for cell-based therapies in tissue remodeling [24–
26]. The advantages of this source of stem cells are that it is
easy accessible and that the harvesting procedure is mini-
mally invasive compared to conventional stem cell sources
like the bone marrow. Additionally, the yield of stem cells
when harvesting from adipose tissue is estimated to be
about 500-fold higher than that of bone marrow [27].
The adipose tissue is harvested by liposuction and the
lipoaspirate is subsequently enzymatically digested by col-
lagenase and fractionated into the SVF. This heterogeneous
population is composed of many types of cells among these
the stromal stem cells. The following surface markers
identify the stromal population of the SVF phenotypically:
CD13? CD73? CD90? CD34? CD31- CD45- [2].
When cultured the cell population becomes more homoge-
neous as non-adherent cells are eliminated and viable cells
proliferate. The resulting population of ASCs have positive
markers in common with other mesenchymal stromal/stem
cells (MSCs), includingCD105, CD44, CD73, CD90, CD13,
and CD29, and negative for CD31 and CD45. The marker
CD34 is generally expressed in a lower degree byASCs but is
dependent on culture conditions and the marker tends to
diminish with increasing passages [28, 29]. Additionally, the
ASCs are positive for CD36 and negative for CD106 dis-
tinguishing them from bone marrow-derived MSCs [14].
The SVF and ASC populations are multipotent and are
therefore able to differentiate along several lineages (ec-
todermal [30], endodermal [31] and mesenchymal [32, 33])
to terminally differentiated cells. Additionally, the cells are
able to secrete a series of growth factors, immune modu-
latory factors, and cytokines [34].
As we report herein, many studies have showed promising
results using SVF or ASCs in CAL. Several possible mecha-
nisms for this positive effect on fat graft survival have been
suggested (Fig. 1) [35]. Firstly, themultipotent capacity of the
cells allows them to differentiate into cell types such as adi-
pocytes or endothelial cells [15, 36], in this way contributing
to the regeneration of the adipose tissue or promotion of
angiogenesis, respectively. Secondly, ASCs may remain as
original ASCs in the graft [11]. Finally, the mechanism could
be a paracrine kind. ASCs secrete a wide range of factors that
may influence the surrounding host tissue. An example is the
growth factorsHGFandSDF-1 that are released in response to
injury and promote angiogenesis [37–39]. Regardless of the
underlying mechanism, lipoaspirate enriched with SVF or
ASCs seems to affect the commonly occurring postoperative
atrophy and replacement process of grafted fat [8], making
CAL a promising treatment.
Data Acquisition
A systematic search was performed on PubMed from
January 2000 to March 2015 to identify all animal and
human studies in which CAL with ASCs or SVF had been
compared with regular lipotransfer. The following search
strategy was used ‘‘[(adipose stem cell) OR (adipose stro-
mal cell) OR (adipose regenerative cell) OR (SVF)] AND
[(fat graft) OR (lipotransfer) OR (lipofilling)].’’ The search
was performed independently in duplicate by authors NMT
and JAS. This search resulted in 204 studies. Review
articles (29) and non-English language articles (14) were
excluded leaving 161 articles. Inclusion criteria were any
animal or human study, in which CAL was compared with
non-CAL. All abstracts of remaining papers were skimmed
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and full text copies of relevant papers were acquired (60
not relevant based on abstract). From the remaining papers,
27 were included for analysis. See Fig. 2 for schematic
overview of the search process. Reference lists of included
papers were checked for additional studies without further
findings. A similar search was performed on EmBase.
All included preclinical studieswere checked for at least one
outcome variable regarding lipotransfer retention rate using
weight or volumemeasurements, histologic assessment of graft
morphology using standardized scoring that was explained or
capillary density with explanation for how the measurement
was performed. All included clinical studies were checked for
at least one radiologic outcome variable regarding lipotransfer
retention [computed tomography (CT) or magnetic resonance
imaging (MRI)]. Data adhering to these principles were




Fifteen studies were identified in which immunodeficient
animals were used. One study used rats [40] and the
remaining studies used mice [11, 15, 18–20, 40–49]. Dosage
for cell enrichment ranged from 5 9 105 to 2 9 107 cells/ml
of lipoaspirate. In all studies, human tissue and cells were
used [11, 18–20, 40–47] except for three in which rat [49] or
mice [15, 48] tissue and cellswere used. The relative survival
improvement for simple CAL ranged from 1.19- to 2.37-fold
compared with their respective control group, which con-
sisted of regular lipotransfer.
Two studies found no significant difference in survival
rate of which one had used SVF [40] and the other ASCs
[42]. One study did not measure survival rate [41]. Four
studies systematically examined the morphology of the
explanted fat grafts of which two found significantly better
integrity and less cyst formation [40, 42, 43, 49]. Many of
the remaining studies described better morphology with
more viable adipocytes, less necrosis, and cyst formation
with CAL but they did not provide either sufficient
description of their method or statistics to substantiate
these claims. Ten studies examined capillary density of
which 9 found a significantly increased capillary density
with CAL. See Table 1.
Five studies were identified, in which immunocompetent
animals were used of which two used rodents (allogeneic
cells) [16, 50] and the remaining studies used rabbits (au-
tologous cells) [17, 51, 52]. The relative survival
improvement for CAL ranged from 1.29- to 4.14-fold
Fig. 1 Schematic
representation of the principle
of cell-assisted lipotransfer and
the possible mechanisms of
action of the ASCs
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compared with their respective control group. One study
did not measure survival rate [17]. Three out of the four
studies that systematically examined the morphology of the
explanted fat grafts showed a significantly better integrity
and less cyst formation with CAL. Two studies examined
the capillary density and both found a significantly
increased capillary density with CAL. See Table 2.
In summary of all preclinical studies, a majority of
studies that measured survival rate found a significant
increase in survival rate when using CAL (16 out of 18
studies). Although many studies noticed an improved
morphology with CAL only 8 studies examined the mor-
phology systematically of which 5 studies showed an
improvement in morphology. Capillary density was
examined in the majority of studies and 11 out of 12 studies
found an increased capillary density.
Number of Administered ASCs
Four of the included studies used different dosages of cells.
This is a very important area because the number of cells
needed for the optimal augmented effect of CAL is not
known. Ko et al. compared the use of 1 9 106 and 1 9 107
ASCs in a nude mouse model using human cryopreserved
lipoaspirates and cells transplanted to the scalp [42]. Vol-
umetric and weight analysis was performed at both 4 and
15 weeks postoperatively, and whereas the graft retention
at 4 weeks marginally favored the higher dose when
looking at weight but not volume there was no difference at
all at 15 weeks between any of the groups with control.
This study should be interpreted with caution as the via-
bility of the cryopreserved lipoaspirates and cells was not
evaluated.
Records idenﬁed through 
Pubmed/Medline
(n = 204 )
Records screened
(n =  161)
Exclusion:
60 Not related to subject 
of interest
Full-text arcles assessed for 
eligibility
(n =  101 )
Exclusion:
74 Not related to subject 
of interest






Studies included in qualitave 
synthesis
(n =  27)
Fig. 2 Flow diagram of search
strategy
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Luo et al. compared four different dosages of human
ASCs that were sorted for CD31 before being cultured in
endothelial growth medium [44]. The dosages ranged from
1 to 8 9 106 ASCs/ml and were injected into the dorsum of
immunodeficient mice (0.5 ml of lipoaspirate per injec-
tion). They found that the highest dose of 8 9 106 cells
yielded the best retention rate, which was significantly
better than all other groups.
Ni et al. performed a study that compared four different
fat tissue to SVF ratios in an immunocompetent rabbit
model [52]. They used a total of 0.8 g with varying ratios
between fat and SVF. The ratios were 1/3, 1/4, 1/5, and 1/6
SVF. Although all SVF groups survived significantly better
than the control group, the ratio of 1/4 was significantly
better than the lower ratios. The ratios of 1/3 and 1/4 were
very similar. These two studies suggest that there could be
a lower threshold for the amount of cells needed for a
beneficial effect.
Li et al. compared four different ASC concentrations
ranging from 1 9 104–1 9 107 ASCs/ml of fat [43]. All fat
grafts were supplemented with the same amount of plate-
let-rich plasma (PRP). At a follow-up of 90 days they
found a significantly improved survival rate of transplanted
fat using 1 9 105 ASCs compared with the other groups
which was complemented by an increased capillary density
and also increased normal adipose tissue structure. This
study suggests a possible upper limit of the amount of cells
to enrich the fat in order to obtain optimal results. This is a
somewhat surprising result as 1 ml of fat is considered to
have more than 1 9 105 of SVF with a normal range of
2–7 9 105 per ml of fat [53–55].
The Effect of Culturing ASCs
Several authors have tried to compare the efficacy of SVF
and ASCs using many different animal models. Bai et al.
Table 1 Overview of all preclinical studies using immunodeficient animals






Ko et al. [42] Human Mice ASC Skull 1 9 106–1 9 107 n.s n.s n.s 0
Matsumoto et al. [11] Human Mice SVF Dorsum d.u. 1.37 : 0 0
Xu et al. [45] Human Mice ASC Dorsum 2 9 107 2.37 : 0 :
Li et al. [20] Human Mice SVF Dorsum 2.5 9 106 2.18 : 0 :
Li et al. [43] Human Mice ASC Dorsum 1 9 104–1 9 107 1.46 : : :
Luo et al. [19] Human Mice ASC Dorsum 3.3 9 106 1.28 : 0 :
Lu et al. [18] Human Mice ASC Dorsum 1.67 9 107 2.22 : 0 :
Garza et al. [41] Human Mice ASC Dorsum 1 9 106 0 0 0 :
Jiang et al. [47] Human Mice ASC Dorsum 5 9 105 1.48 : 0 :
Conde-Green et al. [40] Human Rat SVF Dorsum 6.67 9 106 n.s n.s n.s n.s
Zhou et al. [49] Rat Mice SVF Dorsum d.u. 1.56 : : :
Moseley [15] Mice Mice SVF/ASC Skull d.u. 2.5 SVF
ASC n.s
: 0 0
Fu et al. [48] Mice Mice SVF Skull 5 9 105 1.19 : 0 0
Zhu et al. [46] Human Mice SVF Dorsum 2 9 106 1.19 : 0 0
Luo et al. [44] Human Mice ASC Dorsum 1–8 9 106 0 : 0 :
d.u dose unknown, n.s. not significant, 0 not measured, : improved/increased













Zhu et al. [50] Allogenic Mice SVF Skull 8.33 9 107 2.06 : : :
He et al. [51] Autologous Rabbit SVF Dorsum d.u. 2.13 : n.s 0
Ni et al. [52] Autologous Rabbit SVF Dorsum d.u. 1.29 : 0 0
Seyhan et al. [16] Allogeneic Rat ASC Skull d.u. 4.14 : : 0
Piccinno et al. [17] Autologous Rabbit ASC Upper lip 5 9 106 0 0 : :
d.u dose unknown, n.s. not significant, 0 not measured, : improved/increased
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[56] could not demonstrate any difference in effect in a
myocardial infarction model, whereas Harada et al. [57]
and Sermon et al. [58] both showed an edge toward SVF in
an ischemic limb and experimental autoimmune
encephalomyelitis model, respectively. Only the study by
Moseley et al. [15] compared the use of SVF and ASCs but
this study did not describe the methodology or results in
detail. A relative survival rate improvement of 2.5 was seen
in the SVF group compared with control, whereas the
ASCs group only showed a trend toward improvement but
the difference was not significant.
In total, eleven studies used ASCs for CAL of which two
did not evaluate survival rate. Two out of the remaining
nine studies failed to demonstrate any difference from the
control group. In total, ten studies used SVF of which one
did not evaluate survival rate. One out of the remaining
eight studies did not differ from the control group. With the
present evidence available not much can be concluded
regarding which cell population (fresh or cultured) is
optimal.
The Effect of ASCs Modification and/or Supplementation
Several studies have examined if the benefit of CAL can be
augmented with either genetic modification or supple-
mented with certain growth factors. All studies in this field
suggest that CAL can be augmented with either modifica-
tion or supplementation.
PRP has been used in several studies as an adjunct to
stem cell treatment and this is also true for CAL. Seyhan
et al. compared the use of CAL with ASCs with or without
PRP or lipotransfer with PRP alone [16]. They found that
CAL ? PRP resulted in the best retention rate and the
relative improvement was 1.4 when comparing with CAL
alone.
VEGF stimulates angiogenesis and is secreted by ASCs
and the paracrine effect of these cells is due partly to the
secretion of this growth factor. Studies have either genet-
ically modified cells to overexpress VEGF [18] or sup-
plemented the cells with VEGF polylactic acid nano-
sustained release microspheres for a sustained additional
release of VEGF independent of the cells [20]. Both these
studies showed an additional benefit of VEGF with a rel-
ative improvement in survival rate of 1.23 and 1.15,
respectively, compared with regular CAL. This was sta-
tistically significant in both studies.
Luo et al. examined if supplementing CAL with 17-b
Estradiol (E2) would yield greater survival rate [19]. A
survival rate of 76.9 ? 1.9 versus 71.2 ? 1.7 % was seen
for CAL ? E2 and CAL only, respectively, which was
statistically significant. Their histologic examination
revealed a greater capillary density in the CAL ? E2
group.
Jiang et al. found that supplementing CAL with basic
fibroblast growth factor (bFGF) resulted in both higher sur-
vival rate of 81 ? 5 versus 71 ? 7 % and a higher vessel
density when compared with the regular CAL group [47].
Human Studies
Non-randomized Studies
Although many case series with CAL have been published
since Yoshimura first presented the technique for human
use not many have done so in a proper clinical trial setting
[59]. Several authors have published case series using CAL
but have not compared it with regular lipotransfer [22, 60].
A total of seven human studies were found (two random-
ized clinical trials) where CAL was compared with regular
lipotransfer and outcome was assessed with either CT or
MRI. In all studies except one, an increase in relative
survival rate of CAL compared with regular lipotransfer is
seen. See Table 3 for an overview of human studies.
Li et al. conducted a trial for patients undergoing lipo-
transfer for facial contouring where 26 patients underwent
CAL with SVF and 12 patients underwent non-CAL based
on a voluntary principle [61]. Patients underwent CT scans
and had photographs taken before the procedure and
6 months after. For the CAL group, approximately the
same amount of lipoaspirate was used for SVF isolation as
Table 3 Overview of all human studies comparing cell-assisted lipotransfer with regular lipotransfer
Study design Recipient site Cell type Radiologic method Relative survival rate
Li et al. [61] Cohort study Face SVF CT 1.4
Gentile et al. [62] Cohort study Face SVF MRI 1.6
Gentile et al. [63] Cohort study Breast SVF MRI 1.6
Koh et al. [65] Randomized clinical trial Face ASC CT 1.5
Peltoniemi et al. [23] Cohort study Breast SVF MRI n.s
Chang et al. [64] Cohort study Face SVF CT 1.17
Kølle et al. [66] Randomized clinical trial Arm ASC MRI 5.0
n.s. not significant
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was injected into the face. As determined by CT images
they found a significantly better survival rate in the CAL
group, which was 64.8 ? 10.2 versus 46.4 ? 9.3 %
(p\ 0.01).
Gentile et al. conducted a trial for patients undergoing
lipotransfer because of facial scarring for various reasons
[62]. They included 30 patients in three groups with 10
patients in each group. The groups were CAL with SVF,
lipotransfer with PRP, and regular lipotransfer. Results
were evaluated with both MRI and ultrasonography (US).
A survival rate of 63 % was found for CAL versus 39 % in
the control group which was statistically significant. This
study did not describe their allocation algorithm or if any
blinding was performed. The amount of lipoaspirate used
for SVF isolation as well as the amount of fat transferred in
each group was not described.
Gentile et al. conducted a trial for patients undergoing
breast reconstruction with lipotransfer [63]. They included
10 patients that received CAL with SVF, 13 patients that
received lipotransfer ? PRP, and a control group of 10
patients with regular lipotransfer. Results were evaluated
by MRI. They used approximately half of the lipoaspirate
for SVF isolation which was then mixed with the remain-
ing lipoaspirate before injection. Survival rate after 1 year
was 63 % for the CAL versus 39 % in the control group
which was statistically significant. This study did not
describe their allocation algorithm or if any blinding was
performed.
Peltoniemi et al. have compared SVF-enriched lipo-
transfer with regular lipotransfer for breast augmentation
using the water-assisted liposuction technique in 18
patients [23]. Patients were offered to pay additional
money for the SVF enrichment and as such the study was
not randomized or blinded. They did not count the amount
of SVF cells used for enrichment but the ratio between fat
used for SVF isolation and the fat graft itself was
approximately 1:1. The survival rate of CAL was 74 versus
79 % in the regular lipotransfer group measured using
MRI, which was not statistically significant.
Chang et al. compared SVF-enriched lipotransfer with
regular lipotransfer in patients with hemifacial atrophy
with 10 patients in each group [64]. They did not count the
number of SVF cells used but the ratio between fat used for
transfer and SVF isolation was 1:1. Results were evaluated
by changes in volume estimated by CT scans up to
6 months postoperatively. A significantly higher survival
rate was seen in the CAL group 68.3 versus 58.5 % in the
regular lipotransfer group.
Randomized Studies
Koh et al. have conducted a study with 10 patients with
Parry–Romberg disease who underwent lipotransfer to the
face where 5 patients underwent CAL [65]. All patients had
a primary and secondary lipotransfer (secondary 14 days
after primary lipotransfer) and in the time period between
these two procedures ASCs were cultured up to passage 3
and regardless of amount of fat that was transplanted
1 9 107 ASCs were co-injected at the secondary proce-
dure. Results were evaluated with CT scans and 3D pho-
tography after 6 months. The CAL group had undergone
larger lipotransfers compared with the control group. The
resorption level was still smaller in the CAL group at 20.59
versus 46.81 % in the control group, which was statistically
significant. There are several pitfalls in this study as
blinding and allocation of patients was not described. In
addition the fat graft used was stored fat, but it was not
described how the tissue was stored and the viability of the
injected tissue was not examined.
Kølle et al. have conducted the so far only blinded
randomized clinical trial comparing the survival of CAL
enriched with autologous ASCs versus regular lipotransfer
[66]. Ten patients completed the trial in which a bolus
injection of fat was injected to the upper arm on each site
with a total volume of 34 ml. On one side, the fat graft was
enriched with 2.2 9 107 ASCs/ml of fat and on the other
side the fat graft was not enriched. The patients were fol-
lowed for 121 days when the grafts were explanted for
histologic analysis. MRI was performed preoperatively,
immediately after lipotransfer and after 121 days. The
survival rate for ASC-enriched grafts and control grafts,
respectively, was 80.9 % (76.6–85.2) and 16.3 %
(11.1–21.4) of the initial volumes (p\ 0.0001) yielding a
relative survival improvement of 5.0. Histologic analysis
revealed a significantly higher quality of the remaining
graft but interestingly the capillary density was not
increased as most preclinical studies have shown. Although
the strength of this study was the possibility to explant the
graft for histologic analysis, it is also the downfall, as the
injection method using a bolus injection instead of opting
for the micro-droplet injection technique, surely has
affected survival of the graft.
Discussion
In this review, we have presented the current evidence for
the efficacy of CAL. In preclinical studies, both SVF and
ASCs seem to provide evidence for the superiority of CAL.
The clinical studies using SVF are not as well designed as
studies using ASCs but they show promising results.
Despite the many published studies so far it is still
unknown, how many cells are needed for the optimal sur-
vival rate and if it is even worth sacrificing lipoaspirate for
stem cell isolation when this could have been used directly
or at a later time point for additional lipotransfer. This
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question is very important when using SVF because a large
volume is needed to obtain meaningful cell enrichment.
When using ASCs this is less important as cells can be
culture-expanded; however, this also has the pitfall of
prolonging the treatment to a two-stage procedure. It is
apparent that although no clear-cut conclusion can be made
regarding using SVF or ASC, they both have their strengths
and limitations when taking a practical, legal, and logistic
approach. The pitfalls of both cell populations beg the
question of whether the same results could be obtained by
performing two simple lipotransfers instead. This is espe-
cially true if your regular technique results in more than
70 % survival rate, because this leaves very little room for
improvement with CAL. The survival rate of the regular
lipotransfer in the human studies varied from 16.3 to 79 %
and this impacts the window of opportunity for CAL to
improve the treatment. The only properly design random-
ized clinical trial using a bolus technique resulted in only
16.3 % survival of regular lipotransfer and it would have
been very interesting to see the results of a similar study
using a more conventional injection technique.
The quality of reporting outcomes in preclinical studies
should be standardized so that they always include a vol-
umetric/weight retention analysis and morphologic char-
acterization including vessel density of the retained fat as
lipotransfer is not only about volume but also quality of the
volume. In the same manner, clinical studies should all
include an objective volumetric assessment of CAL using
either CT or MRI before and after surgery.
Another crucial aspect of CAL is the safety of the
technique. Several in vitro and in vivo experimental studies
have suggested that SVF and ASCs can support tumor
growth through paracrine mechanisms [67–69]. The con-
cern is perhaps not so much that CAL or even just regular
lipotransfer can act tumorigenic but rather can support and
promote the growth of cancer cells if any are left behind
after primary treatment. Lipotransfer is especially useful
for breast reconstruction following cancer. Especially in
cases where breast-conserving surgery has been performed,
it seems reasonable to wait a few years after surgery before
performing lipotransfer. More studies are needed to
examine if CAL and lipotransfer are correlated with
increased cancer recurrence risk in relevant patient popu-
lations [70, 71].
Future Perspectives
For soft tissue reconstruction, CAL is at a crucial time
point where the transition from very exciting preclinical
results to clinical therapy is in process. The published
human studies so far show promising results, and further
properly designed clinical trials are needed in relevant
patient groups to establish in which cases this technique
could be relevant and superior to two separate regular
lipotransfers.
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